Die Übersetzung dieser Seite ist experimentell und in Entwicklung. Wir freuen uns über Ihr !

Becton Dickinson Zukünftiges Wachstum

Future Kriterienprüfungen 3/6

Becton Dickinson wird ein jährliches Gewinn- und Umsatzwachstum von 18.1% bzw. 5.4% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 17.6% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 15.6% betragen.

Wichtige Informationen

18.0%

Wachstumsrate der Gewinne

17.5%

EPS-Wachstumsrate

Medical Equipment Gewinnwachstum	18.4%
Wachstumsrate der Einnahmen	5.4%
Zukünftige Eigenkapitalrendite	15.6%
Analystenabdeckung	Good
Zuletzt aktualisiert	04 Jun 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Gewinn- und Umsatzwachstumsprognosen

BUL:BOX - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
9/30/2026	22,642	2,808	4,108	5,079	11
9/30/2025	21,425	2,479	4,150	4,694	16
9/30/2024	20,249	2,094	2,973	3,834	16
3/31/2024	19,716	1,364	3,025	3,760	N/A
12/31/2023	19,492	1,265	2,649	3,431	N/A
9/30/2023	19,372	1,470	2,115	2,989	N/A
6/30/2023	19,046	1,582	1,878	2,773	N/A
3/31/2023	18,809	1,556	1,009	1,966	N/A
12/31/2022	18,738	1,486	1,361	2,359	N/A
9/30/2022	18,870	1,545	1,661	2,634	N/A
6/30/2022	18,958	1,412	1,465	2,575	N/A
3/31/2022	18,924	1,430	2,041	3,141	N/A
12/31/2021	18,534	1,079	2,620	3,751	N/A
9/30/2021	19,131	1,514	3,453	4,647	N/A
6/30/2021	19,066	1,486	4,222	5,177	N/A
3/31/2021	18,313	1,379	4,150	5,064	N/A
12/31/2020	18,207	1,507	3,476	4,359	N/A
9/30/2020	16,074	245	2,728	3,497	N/A
6/30/2020	16,917	786	2,474	3,429	N/A
3/31/2020	17,414	923	2,509	3,499	N/A
12/31/2019	17,355	760	2,835	3,798	N/A
9/30/2019	17,290	1,081	2,373	3,330	N/A
6/30/2019	17,108	784	2,359	3,265	N/A
3/31/2019	17,036	926	2,009	2,875	N/A
12/31/2018	17,063	894	1,906	2,790	N/A
9/30/2018	15,983	159	1,970	2,865	N/A
6/30/2018	14,747	621	1,837	2,685	N/A
3/31/2018	13,503	-99	1,681	2,527	N/A
12/31/2017	12,251	294	N/A	2,555	N/A
9/30/2017	12,093	1,030	N/A	2,550	N/A
6/30/2017	12,158	759	N/A	2,129	N/A
3/31/2017	12,321	1,314	N/A	2,579	N/A
12/31/2016	12,419	1,309	N/A	2,411	N/A
9/30/2016	12,483	976	N/A	2,559	N/A
6/30/2016	12,312	1,139	N/A	2,532	N/A
3/31/2016	12,234	810	N/A	2,236	N/A
12/31/2015	11,217	688	N/A	1,907	N/A
9/30/2015	10,282	695	N/A	1,730	N/A
6/30/2015	9,410	815	N/A	1,591	N/A
3/31/2015	8,448	1,079	N/A	1,492	N/A
12/31/2014	8,468	1,150	N/A	1,677	N/A
9/30/2014	8,446	1,185	N/A	1,746	N/A
6/30/2014	8,345	974	N/A	1,876	N/A
3/31/2014	8,239	941	N/A	1,830	N/A
12/31/2013	8,169	930	N/A	1,626	N/A
9/30/2013	8,054	929	N/A	1,505	N/A
6/30/2013	7,920	1,114	N/A	1,405	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: BOXDas prognostizierte Gewinnwachstum (18.1% pro Jahr) liegt über der Sparquote (3%).

Ertrag vs. Markt: BOXDie Erträge des Unternehmens (18.1% pro Jahr) werden voraussichtlich schneller wachsen als der Markt BG (12.6% pro Jahr).

Hohe Wachstumserträge: BOXDie Erträge des Unternehmens werden voraussichtlich steigen, jedoch nicht deutlich.

Einnahmen vs. Markt: BOXDie Einnahmen des Unternehmens (5.4% pro Jahr) werden voraussichtlich schneller wachsen als der Markt BG (5.1% pro Jahr).

Hohe Wachstumseinnahmen: BOXDie Einnahmen des Unternehmens (5.4% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: BOXDie Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich niedrig sein (15.6 %).

Becton Dickinson Zukünftiges Wachstum

Future Kriterienprüfungen 3/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Becton, Dickinson and Company Revises Earnings Guidance for the Fiscal Year 2024

Becton, Dickinson and Company Raises Earnings Guidance for the Fiscal Year of 2024

Becton, Dickinson and Company Provides Earnings Guidance for the Fiscal Year 2024

Becton, Dickinson and Company Raises Earnings Guidance for the Fiscal Year 2023

Becton, Dickinson and Company Raises Earnings Guidance for the Fiscal Year 2023

Becton, Dickinson and Company Provides Earnings Guidance for the Year 2023

Recent updates

Becton, Dickinson and Company Revises Earnings Guidance for the Fiscal Year 2024

Second quarter 2024 earnings released: EPS: US$1.86 (vs US$1.54 in 2Q 2023)

Becton, Dickinson and Company Declares Quarterly Dividend, Payable on June 28, 2024

Becton, Dickinson and Company (NYSE:BDX) acquired FlowJo LLC.

Becton, Dickinson and Company to Report Q2, 2024 Results on May 02, 2024

Becton, Dickinson and Company Initiates International Study to Expand Treatment Options for Patients with Peripheral Arterial Disease

Dave Hickey Retires as Executive Vice President and President of the Life Sciences Segment for BD, Effective from July 1, 2024

First quarter 2024 earnings released: EPS: US$0.97 (vs US$1.71 in 1Q 2023)

Becton, Dickinson and Company Raises Earnings Guidance for the Fiscal Year of 2024

Becton, Dickinson and Company Declares Quarterly Dividend, Payable on March 29, 2024

Becton, Dickinson and Company to Report Q1, 2024 Results on Feb 01, 2024

Becton, Dickinson and Company, Annual General Meeting, Jan 23, 2024

BD Receives FDA 510(K) Clearance for Potentially Transformative Fingertip Blood Collection Device

BD Launches Advanced Vascular Access Ultrasound System Designed to Improve Clinician Efficiency

Becton, Dickinson and Company Announces Executive Changes

New minor risk - Earnings quality

Full year 2023 earnings released: EPS: US$5.14 (vs US$5.42 in FY 2022)

Becton, Dickinson and Company Increases Quarterly Dividend, Payable on December 29, 2023

Becton, Dickinson and Company Increases Quarterly Dividend, Payable on December 29, 2023

Becton, Dickinson and Company Provides Earnings Guidance for the Fiscal Year 2024

Now 22% undervalued after recent price drop

Becton, Dickinson and Company Announces Launch of Next-Generation Needle-Free Blood Draw Technology

BD Names Greg Rodetis as Senior Vice President of Investor Relations

Becton, Dickinson and Company to Report Q4, 2023 Results on Nov 09, 2023

Now 21% undervalued

New minor risk - Earnings quality

Becton, Dickinson and Company Raises Earnings Guidance for the Fiscal Year 2023

Third quarter 2023 earnings released: EPS: US$1.37 (vs US$1.29 in 3Q 2022)

Becton, Dickinson and Company Elects Joanne Waldstreicher to the Board and as Member of the Corporate Governance and Nominating Committee and the Quality and Regulatory Committee of the Board

Becton, Dickinson and Company Receives FDA 510(k) Clearance for Updated BD Alaris™? Infusion System

Becton, Dickinson and Company to Report Q3, 2023 Results on Aug 03, 2023

STERIS Corporation agreed to acquire Surgical Instrumentation platform from Becton, Dickinson and Company for $540 million.

Second quarter 2023 earnings released

Becton, Dickinson and Company Raises Earnings Guidance for the Fiscal Year 2023

BD Receives FDA Emergency Use Authorization for COVID-19, Influenza A/B, RSV Combination Test

Becton, Dickinson and Company Introduces High-Throughput Single-Cell Multiomics Platform to Expand Scope of Scientific Discovery

First quarter 2023 earnings released: EPS: US$1.71 (vs US$2.30 in 1Q 2022)

Becton, Dickinson and Company Provides Earnings Guidance for the Year 2023

BD (Becton, Dickinson and Company) Declares Quarterly Dividend, Payable on March 31, 2023

Becton, Dickinson and Company Introduces Fully Automated Robotic Track System for Microbiology Labs

Becton, Dickinson and Company and CerTest Biotec Announce Emergency Use Authorization from U.S. Food and Drug Administration for Molecular Polymerase Chain Reaction Assay for Mpox Virus Detection

Becton, Dickinson and Company Announces Executive Changes

Becton, Dickinson and Company to Report Q1, 2023 Results on Feb 02, 2023

Becton, Dickinson and Company, Annual General Meeting, Jan 24, 2023

Now 20% undervalued

Full year 2022 earnings released: EPS: US$5.42 (vs US$5.23 in FY 2021)

Gewinn- und Umsatzwachstumsprognosen

Analystenprognosen zum zukünftigen Wachstum

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Wachstumsunternehmen entdecken